Stefano Tarantolo - Concepedia

Author

Stefano Tarantolo

Also Known As

S R Tarantolo, S TARANTOLO, S Tarantolo, S. R. Tarantolo, S. TARANTOLO, S. Tarantolo, S.R. Tarantolo, STEFANO R. TARANTOLO, STEFANO TARANTOLO, Stefano R Tarantolo

109

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

University of Nebraska Medical Center Palmetto Hematology Oncology Nebraska Medical Center Nebraska Hematology-Oncology The University of Texas Health Science Center at San Antonio

About

Stefano Tarantolo is an author at University of Nebraska Medical Center specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.1K
2	Cell Biology	6	6	159
3	Health Sciences	4	4	300
4	Blood Transplantation	2	2	149
5	Biomedical Engineering	1	1	43

Stefano Tarantolo

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease Andrew J. Ullmann, Jeffrey H. Lipton, David H. Vesole, New England Journal of Medicine	2007	1.3K
Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel Charles L. Bennett, Jean M. Connors, John Carwile, New England Journal of Medicine	2000	645
Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Deborah L. Darrington, Julie M. Vose, J R Anderson, Journal of Clinical Oncology	1994	338
Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group David F. McDermott, Jeffrey A. Sosman, René González, Journal of Clinical Oncology	2008	249
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, The Lancet Haematology Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor	2019	249
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, The Lancet Haematology Hematological MalignancyMedicineImmunologyClinical TrialsHematology	2019	237
Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial A. Keith Stewart, Robert Vescio, Gary J. Schiller, Journal of Clinical Oncology	2001	198
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study Börje S. Andersson, Ashwin Kashyap, Victor G. Gian, Biology of Blood and Marrow Transplantation	2002	187
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Robert Vescio, Gary J. Schiller, A. Keith Stewart, PubMed	1999	172
Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. Ž Pavletić, Michael R. Bishop, Stefano Tarantolo, Journal of Clinical Oncology TransplantationMarrow TransplantationAllogeneic Bsc TransplantationStem Cell TransplantationHematology	1997	122

Page 1